| Annual Financials | 2023 | 2024 | 2025 | 2026 | TTM |
Revenue  | 14 | 18 | 25 | 47 | 0 |
| Expenses | 13 | 16 | 20 | 39 | 0 |
| EBITDA | 1 | 2 | 5 | 7 | 0 |
| Operating Profit % | 4 % | 9 % | 20 % | 16 % | 0 % |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 1 | 1 | 0 |
| Profit Before Tax | 0 | 1 | 4 | 6 | 0 |
| Tax | 0 | 0 | 1 | 2 | 0 |
| Net Profit | 0 | 1 | 3 | 5 | 0 |
| EPS in ₹ | 1.30 | 5.32 | 6.37 | 7.78 | 0.00 |
Aptus Pharma
Aptus Pharma
229.55
-4.65
(-1.99%)
Market Cap
393.63 Cr
PE Ratio
-
Volume
50,800.00
Day High - Low
238.80 - 229.55
52W High-Low
234.20 - 32.32
Key Fundamentals
Market Cap
393.63 Cr
EPS
7.78
PE Ratio
-
PB Ratio
20.10
Book Value
11.65
EBITDA
7.44
Dividend Yield
0.00 %
Industry
Consumer Goods Sector
Household Appliances Return on Equity
44.50
Debt to Equity
1.79
Actual
Company News
View All News
Aptus Pharma's board will meet on June 12, 2026, to consider raising funds via preferential allotment and borrowings. The trading window is closed until 48 hours after the outcome is disclosed.
Aptus Pharma Promotes Baby Care at Airport
May 22, 2026
May 22, 2026Aptus Pharma Limited has undertaken a brand promotion initiative at Rajkot Hirasar Airport. The company has taken over the Baby Care Room to promote its upcoming baby care and OTC product portfolio.
Aptus Pharma Limited discloses inter-se promoter group share transfers on BSE dated 15.05.2026, involving sales and purchases of equity shares among multiple promoter group members.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,541.50 | #1 1,04,632.76 | 61.20 | #1 24,604.90 | -0.10 | #1 1,680 | -8.19 | 52.48 | |
1,304.40 | 43,160.61 | 114.21 | 14,123.00 | -10.26 | 365 | -51.89 | 50.99 | |
1,570.80 | 32,297.97 | 60.53 | 12,402.00 | 2.98 | 545 | 17.11 | 39.09 | |
7,726.00 | 27,189.08 | 120.63 | 12,186.50 | #1 21.30 | 223 | 36.82 | 51.06 | |
260.45 | 16,770.76 | -71.73 | 8,095.52 | 2.06 | -258 | -409.32 | 37.12 | |
301.60 | 13,172.52 | 42.58 | 5,965.78 | 6.56 | 302 | 23.05 | 40.28 | |
773.75 | 9,816.71 | #1 33.51 | 8,034.20 | -0.94 | 282 | -32.64 | 28.12 | |
439.55 | 8,501.08 | 51.74 | 2,709.06 | 10.51 | 161 | 3.03 | 35.28 | |
544.05 | 7,450.82 | 45.27 | 2,973.57 | 6.60 | 152 | #1 185.14 | 56.48 | |
1,286.00 | 5,210.72 | 34.91 | 5,619.48 | 9.61 | 143 | 125.93 | 63.24 |
Growth Rate
Revenue Growth
89.31 %
Net Income Growth
48.39 %
Cash Flow Change
15.21 %
ROE
-1.51 %
ROCE
105.69 %
EBITDA Margin (Avg.)
-20.35 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 6 | 10 | 22 | 44 |
| Fixed Assets | 1 | 1 | 1 | 3 |
| Current Assets | 6 | 8 | 20 | 35 |
| Capital Work in Progress | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 14 |
| Other Assets | 6 | 9 | 21 | 0 |
| Total Equity & Liabilities | 6 | 10 | 22 | 44 |
| Current Liabilities | 3 | 4 | 12 | 19 |
| Non Current Liabilities | 2 | 4 | 3 | 1 |
| Total Equity | 1 | 2 | 7 | 23 |
| Reserve & Surplus | 1 | 2 | 2 | 17 |
| Share Capital | 0 | 0 | 5 | 7 |
Cash Flow
| Cash Flow | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 0 | 4 |
| Investing Activities | -0 | -0 | -1 |
| Operating Activities | -0 | -2 | -2 |
| Financing Activities | 1 | 3 | 7 |
Share Holding
| % Holding | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | May 2026 |
| Promoter | 72.89 % | 72.89 % | 72.89 % | 72.89 % | 72.89 % |
| FIIs | 10.03 % | 10.03 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 2.80 % | 2.80 % | 0.00 % | 0.00 % | 0.00 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 11.55 % | 11.55 % | 22.97 % | 23.47 % | 23.76 % |
| Others | 2.74 % | 2.74 % | 4.14 % | 3.64 % | 3.35 % |
| No of Share Holders | 9 | 9 | 302 | 337 | 356 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 10 Nov 2025 |  Quarterly Result Announcement | NA | 10 Nov 2025 | 51.68 | 58.20 |
| 27 Apr 2026 | Quarterly Result Announcement | NA | 27 Apr 2026 | 151.58 | 144.20 |
| 12 May 2026 |  Bonus | 3:2 | 12 May 2026 | 148.00 | 172.16 |
Announcements
Closure of Trading Window10 hrs ago
10 hrs agoBoard Meeting Intimation for Intimation Of Board Meeting To Be Held On Friday June 12 2026 And Intimation Regarding Closure Of Trading Window.10 hrs ago
10 hrs agoAnnouncement under Regulation 30 (LODR)-Investor PresentationMay 29, 2026
May 29, 2026Brand Promotion Initiative At Rajkot Hirasar AirportMay 22, 2026
May 22, 2026Disclosure As Per Regulation 7(2) Of SEBI (PIT) Regulations 2015May 15, 2026
May 15, 2026Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations 2011May 14, 2026
May 14, 2026Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations 2011May 14, 2026
May 14, 2026Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations 2011May 14, 2026
May 14, 2026Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations 2011May 14, 2026
May 14, 2026Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations 2011May 14, 2026
May 14, 2026Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations 2011May 14, 2026
May 14, 2026Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations 2011May 13, 2026
May 13, 2026Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations 2011May 13, 2026
May 13, 2026Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations 2011May 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 06, 2026
May 06, 2026Statement Of Deviation(S) Or Variation(S) In Utilization Of Proceeds Of Initial Public Offer Pursuant To Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 28, 2026
Apr 28, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 28, 2026
Apr 28, 2026Intimation Of Record Date For Issue Of Bonus SharesApr 27, 2026
Apr 27, 2026Audited Financial Results For The Half Year And Year Ended On 31St March 2026Apr 27, 2026
Apr 27, 2026Board Meeting Outcome for Outcome Of Board Meeting Held On 27Th April 2026.Apr 27, 2026
Apr 27, 2026Disclosure Regarding Non-Applicability Of Regulation 24A Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 25, 2026
Apr 25, 2026Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotApr 25, 2026
Apr 25, 2026Board Meeting Intimation for Intimation Of Board Meeting For Consideration Of Audited Financial Results For The Half Year/Year Ended On March 31 2026 And Closure Of Trading Window.Apr 20, 2026
Apr 20, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2026
Apr 11, 2026Closure of Trading WindowMar 28, 2026
Mar 28, 2026Newspaper Advertisement Of Notice Of Postal Ballot And E-Voting InformationMar 27, 2026
Mar 27, 2026Board Meeting Outcome for Revised Outcome Of Board Meeting Held On 24/03/2026 Incorporating Additional Details In Compliance With SEBI Circular No. SEBI/HO/CFD/Pod2/CIR/P/0155 Dated November 11 2024.Mar 26, 2026
Mar 26, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotMar 26, 2026
Mar 26, 2026Board Meeting Outcome for Outcome Of Board Meeting Held On March 24 2026Mar 24, 2026
Mar 24, 2026Closure of Trading WindowMar 17, 2026
Mar 17, 2026Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On Tuesday March 24 2026Mar 17, 2026
Mar 17, 2026Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015: Business ExpansionFeb 26, 2026
Feb 26, 2026Intimation Of Award Received: Recognition As Fastest Growing Ethical Pharma CompanyFeb 24, 2026
Feb 24, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 07, 2026
Feb 07, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2026
Jan 10, 2026Press Release- Aptus Pharma Expands OTC Presence In Gujarat Strengthens Cosmeceutical PortfolioDec 12, 2025
Dec 12, 2025Regulation 30 Disclosure - Entry Into The Urology Therapy SegmentNov 21, 2025
Nov 21, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 12, 2025
Nov 12, 2025Intimation Of New Product- ENZYKING SYRUPNov 12, 2025
Nov 12, 2025Intimation Of New Product- SHIROVITA HAIR OIL (AYURVEDIC HAIR OIL)Nov 12, 2025
Nov 12, 2025Unaudited Financial Results For The Half Year Ended On 30Th September 2025Nov 11, 2025
Nov 11, 2025Unaudited Financial Results For The Half Year Ended On 30Th September 2025Nov 10, 2025
Nov 10, 2025Board Meeting Outcome for Board Meeting Outcome For Approval Of Unaudited Financial Results For The Half Year Ended On 30Th September 2025Nov 10, 2025
Nov 10, 2025Board Meeting Intimation for To Consider And Take On Record Of The Un-Audited Financial Results For The Half Year Ended On 30Th September 2025.Nov 01, 2025
Nov 01, 2025Clarification On Price MovementOct 21, 2025
Oct 21, 2025Clarification sought from Aptus Pharma LtdOct 17, 2025
Oct 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Oct 14, 2025Closure of Trading WindowOct 01, 2025
Oct 01, 2025Listing of Equity Shares of Aptus Pharma LtdSep 30, 2025
Sep 30, 2025Technical Indicators
RSI(14)
Overbought 86.39
ATR(14)
Less Volatile 5.63
STOCH(9,6)
Overbought 100.00
STOCH RSI(14)
Overbought 100.00
MACD(12,26)
Bullish 4.02
ADX(14)
Very Strong Trend 50.47
UO(9)
Bearish 91.78
ROC(12)
Uptrend And Accelerating 26.59
WillR(14)
Overbought 0.00
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
